Tissue Engineering & Stem Cell Research 2005

Andrew Oliver andrew.oliver at visiongaingroup.com
Thu Dec 2 18:38:18 EST 2004

Tissue Engineering & Stem Cell Research 2005
12th and 13th January 2005
Marriot Kensington Hotel, London


Visiongain Conferences are please to announce their next conference within
the pharmaceutical sector; 'Tissue Engineering & Stem Cell Research 2005'.
Stem cell therapy offers an opportunity to treat many degenerative diseases
caused by the premature death or malfunction of specific cell types and the
body's failure to replace or restore them. This conference will cover the
main disease areas where progress in stem cell research is taking place
along with a huge emphasis on regional regulatory issues.

**Identify new routes to enter the market
**Discover key market segments and profit from emerging trends in stem cell
**An update on stem cell therapies: CASE STUDIES on treating- spinal cord
injuries, kidney disease,
  gastrointestinal cancers, neurological diseases, myocardial and tooth
**Analyse manufacturing practices and learn how to overcome the challenges
in tissue engineering
**Become up-to-date on regulatory issues: a global and US perspective
**Business Development: commercialisation for drug discovery and cell

**Dr. Jane Lebkowski, Senior Vice President, Regenerative Medicine, Geron
**Julie Gruber Allickson, Technical Director - Laboratory Operations,
Cryo-Cell International
**Dr. Stephen Minger, Scientific Director/ Director of the Stem Cell Biology
Laboratory, CereStem Ltd/ KCL
**Dr. Christopher Bravery, Senior Scientist/Team Leader, Intercytex Limited
**Larry Soler, Vice President of Government Relations, Juvenile Diabetes
Research Foundation International
**Dr. Sara Patel, Head of NeuroImaging Group, ReNeuron
**Dr. Karl Willert, Postdoctoral fellow, Stanford University Medical Center
**Dr Phil Bates, Lecturer in Medical Law, Centre for Medical Law and Ethics,
Kings College London
**Dr Chris Potten, Chairman, Epistem
**David Hill, Scientific Director, Lawson Health Research Institute
**Dr. Lior Gepstein, Head Cardiovascular Research Laboratory,
Technion-Israel Institute of Technology
**Professor Paul Sharpe, Head of Craniofacial Development, Odontis Ltd /
King's College London
**Professor Jon Dobson,Professor of Biophysics & Biomedical Engineering ,
Keele University
**Professor Alicia El Haj, Institute of Science & Technology in Medicine,
Keele University
**Dr. Richard France, Project Manager, RegenTec Ltd
**Professor Harry Moore, Director/ Centre for Stem Cell Biology, Axordia/
University of Sheffield


**Senior Vice President, Regenerative Medicine
**Research Director for Assisted Reproduction and Embryonic Stem Cells
**Vice President, Technology
**Vice President, Therapeutic Development Operations
**Director, Experimental Medicine
**Vice President of Government Relations
**Vice President Clinical Affairs, & Director
**Vice President, Product Development
**Business Development Manager


Places at this event are strictly limited so BOOK YOUR PLACE NOW.
To make a booking on this event, please contact me via phone or email. Book
early to secure a place.


Attend the:
2 Day conference - ONLY GBP1299 plus VAT


Booking is easy, simply contact me:

Andrew Oliver
Sales Manager - Conference Division
Visiongain B2B Conferences
Tel. +44(0)20 8767 6711
Fax. +44(0)20 8767 5001
mailto:andrew.oliver at visiongaingroup.com

B2B Conferences is part of the Visiongain Group


Day One Wednesday 12th January 2005

09:00 Registration and coffee

09:30 Opening remarks from the chair


09:40 CASE STUDY: Advances in Stem Cell Programs- Treating
Spinal Cord Injuries
• How to penetrate the emerging field of regenerative medicine
• Oligodendrocyte progenitors- can they restore normal neural
  - results in animal models: significant functional improvements
• Progress in phase I clinical trials: focus on treatment for acute
  spinal cord injury
• Technologies in this field- licenses and intellectual property
Dr. Jane Lebkowski, Senior Vice President, Regenerative Medicine

10:20 CASE STUDY: Metanephroi Transplantation- Treating
Kidney Disease
• How to develop normal renal structures by transplanting kidney
• Transplanting between species without rejection- how to ensure
  minimal immunosupression, leading to success
• Conclusions: implanted metanephroi have intrinsic ability to
  continue developing and organising into functional tissue
• Advantages over renal transplant or dialysis:
  - better clinical outcome than intermittent dialysis, as filtration
  is continuous and active
  - unlimited supply of organs available by this procedure
Dr. Christopher Bravery, Senior Scientist/Team Leader
Intercytex Limited

11:00 Morning Coffee

11:20 CASE STUDY: in vitro and in vivo Model Systems- Treating
Gastrointestinal Cancers
• in vivo models: using the in situ tumour model ADENOQUANT
  to directly compare tumour and normal tissue responses and
  assess therapeutic index
• Transgenic and xenograft models: how to determine the
  importance of gene pathways and treatment response in
  GI tissue
• in vitro screening assay: PRIMEQUANT to realistically predict
  the in vivo response and allow accurate comparisons of normal
  and matched tumour tissue biology
• How to use assays to assess stem cell regulatory effects to
  hyper- and hypoplasia therapies, wound healing agents and
  mucositis therapies
Professor Chris Potten, Chairman

12:00 CASE STUDY: Development of islets from precursor cells
in vitro and in vivo
• Generation of insulin-producing cells from embryonic stem cells
  or hematopoeitic stem cells
• Trans-differentiation capabilities of other pancreatic cell types
  to islets
• Barriers to clinical application
• Mechanisms of regeneration of islets in vivo
David Hill, Scientific Director
Lawson Health Research Institute

12:40 Lunch

14:00 Can Human Brain Cell Transplantation treat Neurological
• Assess advantages and disadvantages of immortalised stem
  cell lines
• c-Myc gene cell lines: transplant strategies
• Graft effects in animal models of neurodegenerative diseasefunctional
  and structural integration
• How to use stem cells as a platform technology for drug
  - identifying small molecules or proteins to mature a brain stem
  cell into a differentiated cell
  - stem cells for screening potential lead compounds for toxicity
Dr. Sara Patel, Head of NeuroImaging Group

14:40 Myocardial Regeneration Strategies using Human
Embryonic Stem Cells
• Heart cells from human embryonic stem cells- progress to date
  - derivation, in vitro differentiation and implications for basic
  research & clinical applications
• How to use it- development and testing of new drugs, genetic
  studies, engineering tissues, organ transplantation, study
• Myocardial regeneration strategies- replacing the dysfunctional
  myocardium with new contractile tissue
• Regulations in Israel- looking to the future in research
Dr. Lior Gepstein, Head Cardiovascular Research Laboratory
Technion-Israel Institute of Technology

15:20 Afternoon Tea

15:40 CASE STUDY: Regenerative Dentistry- How to Grow a
• How to understand and genetically control the key processes
  forming teeth in the embryo
• Interactions between epithelial and mesenchymal cells
  - how to culture cells to form primordia
• Results from mice populations- tooth rudiments formed from in
  vitro cultures of non-dental stem cell populations
• Can rudiments be transferred to adults? - formation of
  complete teeth and associated bones
Professor Paul Sharpe, Head of Craniofacial Development
Odontis Ltd / King's College London


16:20 Implications of GTP/GMP for Cord Blood Processing
• Moving from Clean Lab to an ISO class 7 Cleanroom
• How the FDA's proposed GTP affects cell processing
• Future Direction: cord blood processing - regulatory impacts
Julie Gruber Allickson, Technical Director - Laboratory Operations
Cryo-Cell International

17:00 Questions and Discussion

17:10 Chairman Summation

17:20 Close of Conference

Day Two Thursday 13th January 2005

09:00 Registration and coffee

09:30 Opening remarks from the chair

An Overview of the Industry
The panel session at the end of Day Two will offer you the chance
to hear from Ray Scraggs, Head Consultant at visiongain on the
most detailed and accurate market information available on Tissue
Engineering and Stem Cell Research.
09:40 Advances in Tissue Regeneration: Human ES Cells,
Growth Factors and Biotherapeutic Molecules

• The sources of stem cell and ES cells- learn about the benefits
  of stem cell technology
• Cell nuclear replacement: the fight against type 1 diabetes and
  Parkinson's disease
• Exploiting novel growth factors: promoting the proliferation and
  lineage-specific propagation of stem cell populations
Dr. Stephen Minger, Scientific Director/ Director of the Stem Cell Biology
CereStem Ltd/ King's College London

10:20 Magnecell's Mechanical Conditioning Bioreactor
Systems: How to Activate Ion Channels
• Update on ex-vivo bone engineering results
  - speed of matrix mineralisation; regulation of genes involved
  in bone growth
• Patent technologies for tissue engineering: mechanisms for
  ex-vivo simulation of the in-vivo stress environment
• Applications of system: drug screening, in-vitro testing and
  stem cell research
• Future areas for growth: ex-vivo magnetic activation of in-vivo
  cellular processes
Professor Jon Dobson,
Professor of Biophysics & Biomedical Engineering/ Co-Founder
and Technical Advisor
Keele University/ Magnecell Limited

11:00 Morning Coffee

11:20 Biodegradable scaffolds - Delivery systems for Cell
• Osteochondral and corneal repair using cell therapies and
  tissue engineering approaches
• Delivery vehicles and biodegradable scaffolds for cell therapies
• Scaffold design and in vitro and in vivo tissue engineering
• Stem Cell targeting
Professor Alicia El Haj, Institute of Science & Technology in Medicine
Keele University

12:00 Self Assembling and Injectable Materials for
Regenerative Medicine
• Injectable biodegradable scaffolds for cell and growth factor
• Crosslinking strategies for scaffold self assembly
• Controlling macroporosity within the scaffold environment
Dr. Richard France, Project Manager
RegenTec Ltd

12:40 Lunch

14:00 Stem Cell Maintenance: Results from Isolating the Wnts
• Potential of isolating Wnt proteins- can stem cells be used
  for bone marrow transplants?
• Wnt signaling: a common theme in animal development
• How do Wnt proteins cause hematopoietic stem cells to divide?
• Analysis: pathways triggering stem cell growth
Dr. Karl Willert, Postdoctoral Fellow
Stanford University Medical Center


14:40 Global Perspective: Legal Framework for Stem Cell
• Global situation: US Federal ban on all bar 60 stem cell lineseffects
  on federally-funded research and privately funded
• What is the legal framework for research in the UK?
• Lack of a co-ordinated global policy: effects on research
• Better results from stem cells derived from bone marrow
  and the placenta than embryonic stem cells
Dr Phil Bates, Lecturer in Medical Law
Centre for Medical Law and Ethics
Kings College London

15:20 Afternoon Tea

15:40 Regulation in the US: Expanding the Current Federal
Policy on Stem Cell Research
• The "Stem Cell Research Enhancement Act of 2004"
• Problems with the existing policy and proposed changes
  to overcome them
• Is adult stem cell research a feasible alternative?
• California's Proposition 71- update on progress
• Slowing down research- JDRF perspective
Larry Soler, Vice President of Government Relations
Juvenile Diabetes Research Foundation International


16:20 Human Embryonic Stem Cells: Commercialisation for
Drug Discovery and Cell Therapy
• Cell lines and quality assurance
• the challenge of generating GMP ES cell lines
• Regulating proliferation and plurioptency
• Markers of differentiation
• Production platforms
Professor Harry Moore, Director/ Centre for Stem Cell Biology
Axordia/ University of Sheffield

17:00 Discussion: Attendees Perspective

Presentation and discussion by Dr. Ray Scraggs of the previous
day’s questionnaire results. An insight will be given into the
market revenues, growth areas, new developments and new
entrants to the Tissue Engineering and Stem Cell Research
industry. This will involve some freeform discussion giving you
the opportunity to engage in knowledge-sharing with fellow
Moderator: Dr. Ray Scraggs, Head Consultant
visiongain Consultancy

17:20 Question and Discussion

17:30 Chairman Summation

17:30 Close of Conference

Terms & Conditions
NB - Due to high demand, we do not 'reserve' or 'hold' places - a request
for an invoice to be raised will be treated as an official booking and will
be subject to the cancellation policy as outlined below.
Cancellations/substitutions and name changes: All bookings carry a 50%
liability after the booking has been made, by post fax, email or web. There
will be no refunds for cancellations received on or after one month before
the start of the conference (e.g. cancellation on or after 20th January for
a conference starting on 20th February). If you decide to cancel after this
date the full invoice remains payable. Conference notes, which are available
on the day, will be sent to you. Unfortunately we are not able to transfer
places between conferences and executive briefings. However if you are
unable to attend the event you may make a substitution/name change at any
time as long as we are informed in writing by e-mail, fax or post. Name
changes and substitutions must be from the same company and are not
transferable between companies or countries.

Indemnity: visiongain Ltd reserve the right to change the
conference/executive briefing content, timing, speakers or venue without
notice. The event may be postponed or cancelled due to acts of terrorism,
war, extreme weather conditions, industrial action, acts of God or any event
beyond the control of visiongain Ltd. If such a situation arises we will
endeavour to reschedule the event. However, visiongain Ltd cannot be held
responsible for any cost, damage or expenses, which may be incurred by the
customer as a consequence of the event being postponed or cancelled. We
therefore strongly advise all customers to take out insurance to cover the
cost of the registration, travel and expenses.

To unsubscribe please reply with unsubscribe in the subject line.

Data protection: Visiongain Ltd gathers and manages data in accordance with
the Data Protection Act 1998. Information contained about you may be used to
update you on visiongain Ltd products and services via post, telephone, fax
or email, unless you state otherwise. If you wish your details to be
amended, please send your request to the Database Manager, visiongain Ltd,
40 Tooting High Street, London, SW17 0RG. Alternatively please reply with
unsubscribe in the subject line. Please allow approximately 7 days for your
removal or update request, you may receive additional pieces of
communication from visiongain Ltd during the transitional period, whilst the
changes come into effect.


More information about the Methods mailing list